Fig. 1
Expression of IGF2BP1 and correlation with patient prognostic parameters. A) Real time expression data showing IGF2BP1 overexpression in ETV6::RUNX1 translocation positive patients (n=43), patients with no known sentinel translocation (n=76, includes patients with altered cytogenetics, n=13) and patients with other translocations (n=48, BCR::ABL1 (n=27), TCF3::PBX1 (n=17), KMT2A (n=4)) B) Western Blot showing protein expression of IGF2BP1 in ETV6-RUNX1 translocation positive and negative samples. GAPDH: internal control. C) WBC counts in B-ALL patient groups (****p<0.0001, ***p < 0.001, **p < 0.01, *p < 0.05) D) Percentage of prednisolone resistant and sensitive patients in ETV6::RUNX1 positive and negative subgroups (chi-square-test) E) Overall and F) Event free survival of B-ALL patients (N = 163) belonging to ETV6::RUNX1 translocation positive group (E6R1+) (n = 43 ), other translocations group (E6R1-) (n = 44 ), No known sentinel translocation group (NKST) (n =76) (Kaplan-Meier method with Log-rank test; ***p < 0.001)